Massachusetts Male Aging Study


Also found in: Acronyms.

Massachusetts Male Aging Study

A cross-sectional survey of ± 1700 men, aged 40–69, sampled from the Boston metropolitan area, which evaluated characteristics of andropause (“male menopause”). According to the study, features of andropause include erectile and vasomotor disturbances, increased fatigue, insomnia, decreased testosterone, and increased luteinising hormone.
Mentioned in ?
References in periodicals archive ?
Erectile dysfunction as a predictor of the metabolic syndrome in aging men: Results from the Massachusetts Male Aging Study.
Performance of Massachusetts Male Aging Study (MMAS) and androgen deficiency in the aging male (ADAM) questionnaires in the prediction of free testosterone in patients aged 40 years or older treated in outpatient regimen.
Construction of surrogate variable for impotence in the Massachusetts male aging study.
In the landmark Massachusetts Male Aging Study, 52 percent of men ages 40 to 70 were characterized as experiencing erectile dysfunction.
Among the better studies is the Massachusetts Male Aging Study (MMAS), conducted by the McKinley group at the New England Research Institute, which utilized a cross-sectional, random sample of 1,700 men between the ages of 40 and 69 to determine changes in testosterone levels (Gray, Feldman, McKinlay, & Longcope, 1991).
To conduct the survey -- part of the 1987 to 1989 Massachusetts Male Aging Study -- trained interviewers went to the men's homes in the Boston area and had them fill out a questionnaire about their sexual activities.
According to the Massachusetts Male Aging Study, 52 percent of men between the ages of 40 and 70 report having some difficulty achieving or maintaining erections.
15) In particular, results from the Massachusetts Male Aging Study indicated that the risk for ED was significantly increased in men with hypertension.
The Massachusetts Male Aging Study found a 50% prevalence of ED among padents with heart disease (J.
SAN DIEGO -- Low serum levels of the adrenal steroid dehydroepiandrosterone and dehydroepiandrosterone sulfate predict increased risk of ischemic heart disease in middle-aged men, according to new data from the Massachusetts Male Aging Study.

Full browser ?